{"id":70191,"date":"2026-07-17T22:29:24","date_gmt":"2026-07-17T14:29:24","guid":{"rendered":"https:\/\/flcube.com\/?p=70191"},"modified":"2026-07-17T22:29:25","modified_gmt":"2026-07-17T14:29:25","slug":"cspc-pharmaceutical-launches-phase-ii-trial-of-albumin-bound-sirolimus-for-rare-vascular-tumor-epithelioid-hemangioendothelioma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70191","title":{"rendered":"CSPC Pharmaceutical Launches Phase II Trial of Albumin-Bound Sirolimus for Rare Vascular Tumor Epithelioid Hemangioendothelioma"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>CSPC Pharmaceutical Group<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1093:HKG\">HKG: 1093<\/a>) announced the initiation of a Phase II clinical trial of <strong>sirolimus (albumin-bound)<\/strong> for the treatment of patients with progressive or symptomatic epithelioid hemangioendothelioma (EHE). The novel intravenous formulation leverages proprietary albumin-binding technology to overcome limitations of oral sirolimus, enabling targeted delivery without corticosteroid premedication for this rare vascular tumor.<\/p>\n\n\n\n<h2 id=\"h-clinical-development-milestone\" class=\"wp-block-heading\">Clinical Development Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>CSPC Pharmaceutical Group (HKG: 1093)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Sirolimus for Injection (Albumin-Bound)<\/td><\/tr><tr><td><strong>Trial Phase<\/strong><\/td><td>Phase II<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Progressive or symptomatic epithelioid hemangioendothelioma (EHE)<\/td><\/tr><tr><td><strong>Classification<\/strong><\/td><td>Class 2.2 improved new drug<\/td><\/tr><tr><td><strong>Trial Design<\/strong><\/td><td>Multi-center, open-label, non-randomized<\/td><\/tr><tr><td><strong>Primary Endpoints<\/strong><\/td><td>Efficacy and safety evaluation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-innovation-amp-technology-platform\" class=\"wp-block-heading\">Product Innovation &amp; Technology Platform<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Active Ingredient:<\/strong> Sirolimus (rapamycin), established mTOR inhibitor<\/li>\n\n\n\n<li><strong>Delivery System:<\/strong> Proprietary human serum albumin encapsulation technology<\/li>\n\n\n\n<li><strong>Key Advantages:<\/strong><\/li>\n\n\n\n<li>Overcomes bioavailability limitations of oral formulations<\/li>\n\n\n\n<li>Achieves sufficient drug concentrations at target sites<\/li>\n\n\n\n<li>Eliminates need for corticosteroid premedication<\/li>\n\n\n\n<li>Enables intravenous administration with improved tolerability<\/li>\n\n\n\n<li><strong>Regulatory Status:<\/strong> Classified as Class 2.2 improved new drug under China&#8217;s regulatory framework<\/li>\n\n\n\n<li><strong>Intellectual Property:<\/strong> Protected by formulation and manufacturing process patents<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-disease-background-amp-unmet-need\" class=\"wp-block-heading\">Disease Background &amp; Unmet Need<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Epithelioid Hemangioendothelioma (EHE):<\/strong> Ultra-rare vascular sarcoma with estimated incidence of 1 per 1 million population<\/li>\n\n\n\n<li><strong>Clinical Challenge:<\/strong> Limited treatment options for progressive or symptomatic disease<\/li>\n\n\n\n<li><strong>Surgical Limitations:<\/strong> Many patients are not candidates for curative surgery due to multifocal or metastatic disease<\/li>\n\n\n\n<li><strong>Current Standard:<\/strong> No approved systemic therapies specifically for EHE; off-label use of various agents with limited efficacy<\/li>\n\n\n\n<li><strong>mTOR Rationale:<\/strong> EHE frequently driven by WWTR1-CAMTA1 fusion leading to mTOR pathway activation<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-trial-design-amp-patient-population\" class=\"wp-block-heading\">Trial Design &amp; Patient Population<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Enrollment Criteria<\/strong><\/td><td>Histologically confirmed progressive or symptomatic EHE<\/td><\/tr><tr><td><strong>Surgical Status<\/strong><\/td><td>Not candidates for curative surgery<\/td><\/tr><tr><td><strong>Therapy Requirement<\/strong><\/td><td>Require systemic therapy per investigator assessment<\/td><\/tr><tr><td><strong>Study Sites<\/strong><\/td><td>Multiple centers across China<\/td><\/tr><tr><td><strong>Treatment Regimen<\/strong><\/td><td>Intravenous albumin-bound sirolimus<\/td><\/tr><tr><td><strong>Safety Monitoring<\/strong><\/td><td>Comprehensive adverse event assessment and laboratory monitoring<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-implications-amp-pipeline-expansion\" class=\"wp-block-heading\">Strategic Implications &amp; Pipeline Expansion<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>mTOR Pathway Portfolio:<\/strong> Expands therapeutic applications of sirolimus beyond transplant immunosuppression<\/li>\n\n\n\n<li><strong>Rare Disease Focus:<\/strong> Addresses significant unmet medical need in orphan oncology indication<\/li>\n\n\n\n<li><strong>Platform Technology:<\/strong> Albumin-binding approach applicable to other poorly soluble compounds<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Class 2.2 designation may enable expedited review and approval process<\/li>\n\n\n\n<li><strong>Commercial Potential:<\/strong> Orphan drug status could support premium pricing and market exclusivity<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-competitive-landscape\" class=\"wp-block-heading\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Rare Sarcoma Market:<\/strong> Limited competition in EHE space with no approved targeted therapies<\/li>\n\n\n\n<li><strong>mTOR Inhibitors:<\/strong> Established safety profile provides development advantage over novel mechanisms<\/li>\n\n\n\n<li><strong>China Biopharma Innovation:<\/strong> Represents advanced formulation development capability among Chinese pharmaceutical companies<\/li>\n\n\n\n<li><strong>Global Opportunity:<\/strong> Potential for international expansion following successful China development<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and market opportunities. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market acceptance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026071601132_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026071601132_c.\"><\/object><a id=\"wp-block-file--media-e8f93769-f249-4e87-bb97-dee8b57e8bac\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026071601132_c.pdf\">2026071601132_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026071601132_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-e8f93769-f249-4e87-bb97-dee8b57e8bac\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CSPC Pharmaceutical Group (HKG: 1093) announced the initiation of a Phase II clinical trial of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,171,855],"class_list":["post-70191","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-cspc-pharmaceutical","tag-hkg-1093"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CSPC Pharmaceutical Launches Phase II Trial of Albumin-Bound Sirolimus for Rare Vascular Tumor Epithelioid Hemangioendothelioma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CSPC Pharmaceutical Group (HKG: 1093) announced the initiation of a Phase II clinical trial of sirolimus (albumin-bound) for the treatment of patients with progressive or symptomatic epithelioid hemangioendothelioma (EHE). The novel intravenous formulation leverages proprietary albumin-binding technology to overcome limitations of oral sirolimus, enabling targeted delivery without corticosteroid premedication for this rare vascular tumor.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70191\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CSPC Pharmaceutical Launches Phase II Trial of Albumin-Bound Sirolimus for Rare Vascular Tumor Epithelioid Hemangioendothelioma\" \/>\n<meta property=\"og:description\" content=\"CSPC Pharmaceutical Group (HKG: 1093) announced the initiation of a Phase II clinical trial of sirolimus (albumin-bound) for the treatment of patients with progressive or symptomatic epithelioid hemangioendothelioma (EHE). The novel intravenous formulation leverages proprietary albumin-binding technology to overcome limitations of oral sirolimus, enabling targeted delivery without corticosteroid premedication for this rare vascular tumor.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70191\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-17T14:29:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-17T14:29:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70191#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70191\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CSPC Pharmaceutical Launches Phase II Trial of Albumin-Bound Sirolimus for Rare Vascular Tumor Epithelioid Hemangioendothelioma\",\"datePublished\":\"2026-07-17T14:29:24+00:00\",\"dateModified\":\"2026-07-17T14:29:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70191\"},\"wordCount\":456,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"CSPC Pharmaceutical\",\"HKG: 1093\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70191#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70191\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70191\",\"name\":\"CSPC Pharmaceutical Launches Phase II Trial of Albumin-Bound Sirolimus for Rare Vascular Tumor Epithelioid Hemangioendothelioma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-17T14:29:24+00:00\",\"dateModified\":\"2026-07-17T14:29:25+00:00\",\"description\":\"CSPC Pharmaceutical Group (HKG: 1093) announced the initiation of a Phase II clinical trial of sirolimus (albumin-bound) for the treatment of patients with progressive or symptomatic epithelioid hemangioendothelioma (EHE). The novel intravenous formulation leverages proprietary albumin-binding technology to overcome limitations of oral sirolimus, enabling targeted delivery without corticosteroid premedication for this rare vascular tumor.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70191#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70191\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70191#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CSPC Pharmaceutical Launches Phase II Trial of Albumin-Bound Sirolimus for Rare Vascular Tumor Epithelioid Hemangioendothelioma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CSPC Pharmaceutical Launches Phase II Trial of Albumin-Bound Sirolimus for Rare Vascular Tumor Epithelioid Hemangioendothelioma - Insight, China&#039;s Pharmaceutical Industry","description":"CSPC Pharmaceutical Group (HKG: 1093) announced the initiation of a Phase II clinical trial of sirolimus (albumin-bound) for the treatment of patients with progressive or symptomatic epithelioid hemangioendothelioma (EHE). The novel intravenous formulation leverages proprietary albumin-binding technology to overcome limitations of oral sirolimus, enabling targeted delivery without corticosteroid premedication for this rare vascular tumor.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70191","og_locale":"en_US","og_type":"article","og_title":"CSPC Pharmaceutical Launches Phase II Trial of Albumin-Bound Sirolimus for Rare Vascular Tumor Epithelioid Hemangioendothelioma","og_description":"CSPC Pharmaceutical Group (HKG: 1093) announced the initiation of a Phase II clinical trial of sirolimus (albumin-bound) for the treatment of patients with progressive or symptomatic epithelioid hemangioendothelioma (EHE). The novel intravenous formulation leverages proprietary albumin-binding technology to overcome limitations of oral sirolimus, enabling targeted delivery without corticosteroid premedication for this rare vascular tumor.","og_url":"https:\/\/flcube.com\/?p=70191","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-17T14:29:24+00:00","article_modified_time":"2026-07-17T14:29:25+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70191#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70191"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CSPC Pharmaceutical Launches Phase II Trial of Albumin-Bound Sirolimus for Rare Vascular Tumor Epithelioid Hemangioendothelioma","datePublished":"2026-07-17T14:29:24+00:00","dateModified":"2026-07-17T14:29:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70191"},"wordCount":456,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","CSPC Pharmaceutical","HKG: 1093"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70191#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70191","url":"https:\/\/flcube.com\/?p=70191","name":"CSPC Pharmaceutical Launches Phase II Trial of Albumin-Bound Sirolimus for Rare Vascular Tumor Epithelioid Hemangioendothelioma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-17T14:29:24+00:00","dateModified":"2026-07-17T14:29:25+00:00","description":"CSPC Pharmaceutical Group (HKG: 1093) announced the initiation of a Phase II clinical trial of sirolimus (albumin-bound) for the treatment of patients with progressive or symptomatic epithelioid hemangioendothelioma (EHE). The novel intravenous formulation leverages proprietary albumin-binding technology to overcome limitations of oral sirolimus, enabling targeted delivery without corticosteroid premedication for this rare vascular tumor.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70191#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70191"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70191#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CSPC Pharmaceutical Launches Phase II Trial of Albumin-Bound Sirolimus for Rare Vascular Tumor Epithelioid Hemangioendothelioma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70191","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70191"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70191\/revisions"}],"predecessor-version":[{"id":70194,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70191\/revisions\/70194"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70191"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70191"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70191"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}